Home / Business and Economy / Cencora Surges on Specialty Drug Demand
Cencora Surges on Specialty Drug Demand
4 Feb
Summary
- Cencora exceeded first-quarter profit expectations.
- Demand for specialty drugs and GLP-1 therapies drove growth.
- The company completed the $5 billion acquisition of OneOncology.
Cencora announced first-quarter financial results that exceeded analyst expectations, driven by strong market demand for specialized medical treatments. The company's performance was significantly bolstered by high sales volumes of GLP-1 drugs, used for diabetes and weight loss, and other specialty medications.
Further strengthening its market position, Cencora successfully completed the $5 billion acquisition of OneOncology in December. This strategic move enhances the company's capabilities within cancer care networks.
As a result of these developments, Cencora has updated its fiscal year 2026 forecast. The company now anticipates adjusted operating income growth to be between 11.5% and 13.5%, an upward revision from its previous projection. Cencora reaffirmed its full-year adjusted profit forecast, signaling continued confidence in its financial trajectory.
